Article
Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial.
Cancer science - 1 Jun 2018
Akamatsu Hiroaki, Katakami Nobuyuki, Okamoto Isamu, Kato Terufumi, Kim Young Hak, Imamura Fumio, Shinkai Masaharu, Hodge Rachel A, Uchida Hirohiko, Hida Toyoaki
Abstract excerpt
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the first-line treatment for patients with EGFR mutant non-small-cell lung cancer (NSCLC). However, most patients become resistant to these drugs, so their disease progresses. Osimertinib, a third-generation EGFR-TKI that can inhibit the kinase even when the common resistance-conferring Thr790Met (T790M) mutation is present, is a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.